Novartis has made adjustments to its manufacturing processes to align with FDA guidelines regarding nitrosamine content in drugs for Ribociclib (Kisqali), which is a potential concern due to the potential carcinogenicity of nitrosamines.
When the product is under development, this is still not clear whether to consider the molecule under advance cancer or not.